**Additional File 5. Utilities by age and health state [1].**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Health state** | **Age <26** | **Age 26–45**  | **Age 46–65**  | **Age >65** |
| No ALVD | 0.980 | 0.947 | 0.913 | 0.860 |
| With ALVD | 0.960 | 0.834 | 0.697 | 0.510 |
| With heart failure | 0.500 | 0.427  | 0.366 | 0.270 |

ALVD, asymptomatic left ventricular dysfunction

### Reference

1. Wong FL, Bhatia S, Landier W, Francisco L, Leisenring W, Hudson MM, Armstrong GT, Mertens A, Stovall M, Robison LL, et al: **Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure.** *Ann Intern Med* 2014, **160:**672-683.